SGEN Overview
Upcoming Projects (SGEN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (SGEN)
-
Discussing the potential of Astellas Pharma's Padcev (enfortumab vedotin-ejfv) in combo with Merck’s Keytruda (pembrolizumab), as a recently approved treatment option for patients with urothelial cancer.
Tickers: SGEN, MRK
Executed On: Feb 07, 2024 at 12:00 PM EST -
A Second View: Investigating the phase III clinical trial results of enfortumab vedotin in combination with pembrolizumab presented at ESMO 2023
Tickers: SGEN, MRK
Executed On: Nov 06, 2023 at 02:00 PM EST -
Investigating the phase III clinical trial results of enfortumab vedotin in combination with pembrolizumab presented at ESMO 2023
Tickers: SGEN, MRK
Executed On: Nov 02, 2023 at 03:00 PM EDT -
A second view: discussing the standard of care and the recent FDA Approval for Adcetris (brentuximab vedotin) in combination with chemotherapy for treatment of certain children with Hodgkin lymphoma
Ticker: SGEN
Executed On: Dec 14, 2022 at 01:00 PM EST -
Discussing the standard of care and the recent FDA Approval for Adcetris (brentuximab vedotin) in combination with chemotherapy for treatment of certain children with Hodgkin lymphoma
Ticker: SGEN
Executed On: Nov 28, 2022 at 03:00 PM EST -
Examining Tivdak (tisotumab vedotin) for recurrent or metastatic cervical cancer following chemotherapy progression
Ticker: SGEN
Executed On: Mar 03, 2022 at 04:00 PM EST
Upcoming & Overdue Catalysts (SGEN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (SGEN)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
